Dr. Myles Minter
Recent Articles about Alto Neuroscience Inc.
Biotech to Fast Track Phase 3 Depression Trial 10/30/2025
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
